Medical News Today: Could a once-daily pill for seizures also treat Alzheimer’s disease?
https://www.medicalnewstoday.com/articles/could-a-once-daily-pill-for-seizures-also-treat-alzheimers-disease
Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele
• The Phase 2B trial showed 40% less clinical decline and significantly reduced atrophy of the entorhinal cortex, a key marker of disease progression, compared to placebo in ApoE-4 non- carriers with MCI due to AD • Patients were given…
AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit
Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101 Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression Consistent with a decrease in clinical and cognitive progression (CDR…
AgeneBio leadership presents at American Society for Experimental Neurotherapeutics Annual Meeting
AGB101 for the treatment of neuropsychiatric symptoms in Parkinson’s disease Presenter: Arnold Bakker, Ph.D., Johns Hopkins University Abstract Authors: Arnold Bakker, Gregory Pontone, Richard Mohs, Michela Gallagher Poster Presentation Hippocampal hyperactivity is a pathological hallmark of Alzheimer’s disease (AD) and…
Richard Mohs, AgeneBio Vice President of Clinical Development, Presents at the 15th Annual CTAD Conference
HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics Richard Mohs 1 , Sharon Rosenzweig-Lipson 1 , Arnold Bakker2 , Elizabeth Chang2 , Nisha Rani2 ,…
Boosting the Brain’s Brakes to Beat Memory Loss
Overactivity in the hippocampus, likely tied to lack of inhibition, underlies some age-related cognitive decline. Targeting those circuits shows early promise in slowing memory loss. Read More: “Boosting the Brain’s Brakes to Beat Memory Loss”
AgeneBio CEO Michela Gallagher and Vice President of Research and Development Sharon Rosenzweig-Lipson Present at Biomarkers for Alzheimer’s Disease 2021
Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The Hope4MCI Trial
Dr. Sharon Rosenzweig-Lipson, Vice President of Research and Development, Presents at Alzheimer’s Association International Conference
AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease
– Topline results expected in November 2022 BALTIMORE, April 21, 2021 — AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer’s…
Richard Mohs, AgeneBio VP for Clinical Development, Presents at 2021 NIH Alzheimer Disease Summit
AGB101 to Slow the Progression of MCI in Alzheimer’s Disease
